Psoriasis

LATEST NEWS

Evaluating the Safety of Adalimumab for Pediatric Plaque Psoriasis

By

Emily Pond

Safety data for adalimumab therapy for plaque psoriasis in children is derived from studies in adults, which undercores the need for dedicated pediatric research.

Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis

By

Brian Park, PharmD

Amgen announced positive topline results from the phase 3 study of apremilast (Otezla®), a phosphodiesterase 4 (PDE4) inhibitor, for the treatment of adults with mild to moderate plaque psoriasis.

Ixekizumab Superior to Secukinumab in Providing More Quality-Adjusted Life-Years in Psoriatic Arthritis

By

Dermatology Advisor Contributing Writer

Researchers conducted cost-effectiveness analyses to compare ixekizumab and secukinumab in psoriatic arthritis and moderate to severe plaque psoriasis.

Ustekinumab, Secukinumab, and Ixekizumab Comparable for Plaque Psoriasis

By

Dermatology Advisor Contributing Writer

Ustekinumab, secukinumab, and ixekizumab were compared for clinical effectiveness and associated adverse events in the treatment of plaque psoriasis.

BIOBADADERM Registry Identifies, Compares Safety Profiles of Several Systemic Treatments for Psoriasis

By

Brandon May

Comparative safety data in real-life settings from 9 psoriasis treatments could aid clinicians in selecting the most appropriate treatments for their patients.

Anti-TNF Agents May Lower Alzheimer Disease Risk for Patients With Psoriasis, Rheumatoid Arthritis

By

Emily Pond

A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.

Are Patients With Psoriasis at Increased Risk for Serious Infection, Hospitalization?

By

Emily Pond

A large-scale study assesses the risk for serious infection and hospitalization in patients with psoriasis.

Apremilast Improves Psoriatic Disease and Cardiometabolic Markers

By

Brandon May

A novel study assesses the safety and efficacy of apremilast in patients with psoriasis and evaluates the treatment as a metabolic modulator.

Registries Established for Patients With Psoriasis, Atopic Dermatitis, and COVID-19

By

Heidi W. Moore

New registries have been established to capture emerging data on patients with psoriasis and atopic dermatitis who have COVID-19.

Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection

By

Heidi W. Moore

A study from Italy reports severe outcomes related to the COVID-19 infection in patients with chronic plaque psoriasis receiving immunosuppressive therapies.